Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer.
Higher body mass index (BMI) appears to correlate with better outcomes in colorectal cancer patients receiving anti-PD-1 therapy, but further research is needed to confirm these findings.
Where it sits
this study against the rest of the l-carnitine (levocarnitine) corpusSummary and findings
This study investigated the influence of body mass index (BMI) and dyslipidemia on progression-free survival (PFS) in colorectal cancer (CRC) patients treated with anti-PD-1 therapy. A total of 142 patients who completed at least 2 cycles of treatment were analyzed. Patients with BMI ≥ 24 kg/m² showed significantly longer PFS compared to those with normal BMI.
Abstract
<h4>Background</h4>Obesity is one of the primary risk factors for colorectal cancer (CRC) development, but the impact of obesity on therapeutic responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in CRC remains unclear. This retrospective study investigates relationships between body mass index (BMI), dyslipidemia, and clinical characteristics in immune checkpoint inhibitors (ICIs)-treated CRC patients, while analyzing associated metabolic variations.<h4>Methods</h4>Progression-free survival (PFS) was assessed in CRC patients receiving anti-PD-1 therapy, categorized by BMI and dyslipidemia status. Comprehensive lipidomic profiling was performed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to identify metabolic mechanisms underlying therapeutic responses.<h4>Results</h4>This study enrolled 142 CRC patients who completed ≥ 2 cycles of anti-PD-1 therapy. Patients with BMI ≥ 24 kg/m<sup>2</sup> (overweight per Chinese criteria) showed significantly longer PFS compared to normal BMI counterparts (<i>p</i> = 0.001). Multivariate analysis confirmed BMI as an independent prognostic factor for PFS. Moreover, patients with dyslipidemia exhibited extended PFS. Additionally, lipidomic analysis revealed differential pre-treatment levels of phosphatidylcholine (PC), phosphatidylethanolamine-ether (PE-O) and carnitine between the recurrence (R) and non-recurrence (NR) groups, accompanied by an enrichment trend in glycerophospholipid metabolism.<h4>Conclusion</h4>Our findings show that obesity correlates with enhanced ICIs efficacy in CRC patients, potentially mediated through glycerophospholipid metabolic reprogramming. Furthermore, this association is more pronounced in the janus kinases 1/2 (JAK1/2) and β2-microglobulin (B2M) wild-type subgroup. These results support the potential utility of BMI as a predictive biomarker and highlight the need for further exploration of lipid-modulating combination therapeutic strategies.
Background
This paper addresses the impact of obesity on therapeutic responses to anti-PD-1 immunotherapy in colorectal cancer (CRC), a critical area given obesity's role as a risk factor for CRC development. Prior studies have indicated that metabolic factors may influence treatment outcomes, but the specific relationships between body mass index (BMI), dyslipidemia, and immunotherapy efficacy remain unclear. Understanding these relationships could inform treatment strategies and patient management.
Methods
This retrospective study analyzed 142 CRC patients who received anti-PD-1 therapy and completed at least two cycles. Progression-free survival (PFS) was the primary outcome measure, assessed in relation to BMI and dyslipidemia status. Lipidomic profiling was performed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to explore metabolic variations.
Results
Patients with BMI ≥ 24 kg/m² showed significantly longer PFS compared to normal BMI patients (p=0.001). Multivariate analysis confirmed that BMI is an independent prognostic factor for PFS. Additionally, patients with dyslipidemia exhibited extended PFS. Lipidomic analysis revealed differential pre-treatment levels of phosphatidylcholine, phosphatidylethanolamine-ether, and carnitine between recurrence and non-recurrence groups.
Interpretation
The findings suggest that higher BMI may correlate with improved efficacy of anti-PD-1 therapy in CRC patients, potentially through metabolic reprogramming involving glycerophospholipids. While the statistical significance is clear, the clinical significance of these findings requires careful consideration, particularly given the retrospective nature of the study and potential confounding factors. The results imply that BMI could serve as a predictive biomarker, but further research is necessary to validate these associations.
Key findings
- BMI ≥ 24 kg/m² associated with longer PFS, p=0.001.
- 142 CRC patients enrolled who completed ≥ 2 cycles of anti-PD-1 therapy.
- BMI confirmed as independent prognostic factor for PFS.
- Patients with dyslipidemia exhibited extended PFS.
- Differential pre-treatment levels of phosphatidylcholine, phosphatidylethanolamine-ether, and carnitine observed.
Limitations
- Retrospective study design.
- Potential selection bias.
- Small sample size of 142 patients.
- Lipidomic analysis may not fully capture metabolic variations.
- Short follow-up period for assessing long-term outcomes.